MedTrace Logo

A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH

NCT05283993 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2022-04-25

No results posted yet for this study

Summary

The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be included in this study. Clinical characteristics, treatment options and responses will be collected. Peripheral blood, bone marrow aspirate and urine samples before and after the treatment will banked for future research. Our team will focus on the clinical and pathological features of PCDs, the correlation between the minimal residual disease (MRD) status and prognosis, and the role of Tumor Microenvironment (TME) in the pathogenesis and progress of PCDs.

Conditions

  • Multiple Myeloma
  • Amyloidosis
  • Cryoglobulinemia
  • Castleman's Disease
  • Light Chain Deposition Disease
  • Heavy Chain Deposition Disease
  • Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes
  • Smoldering Multiple Myeloma
  • Plasma Cell Leukemia
  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
  • Monoclonal Gammopathy of Renal Significance (MGRS)
  • Monoclonal Gammopathy of Neurological Significance (MGNS)

Interventions

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • Peking University First Hospital

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2030-12-31
Completion
2030-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05283993 on ClinicalTrials.gov